The results of the Exenatide Study of Cardiovascular Event Lowering study show that the glucagon-like peptide-1 receptor agonist has a neutral cardiovascular effect, the investigators have reported at the EASD annual meeting, in Lisbon, Portugal.
With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.
This review summarizes the results of the DEVOTE, CANVAS, EXSCEL, and ACE trials that tested the cardiovascular safety of insulin degludec, canagliflozin, once-weekly exenatide, and acarbose, respectively.
Schnell O et al. Cardiovasc Diabetol 2017;16:128. doi:10.1186/s12933-017-0610-y
Muskiet et al. review the role of glucagon-like peptide 1 (GLP-1) on glucose metabolism, the gut–renal axis, classical renal risk factors, and renal end points in trials of GLP-1 receptor agonists for type 2 diabetes.